3 Reasons Why GlaxoSmithKline plc Could Be Ripe For Takeover

GlaxoSmithKline plc (LON: GSK) could be a major acquisition target – here’s why.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline

Life as an investor in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is tough at the moment. That’s because shares in the pharmaceutical major have fallen by 10% in the last three months alone. Indeed, since the start of 2012, shares in GlaxoSmithKline are down 4%, while the FTSE 100 is up 18% over the same time period.

Looking ahead, though, GlaxoSmithKline could have a bright future. In fact, it could be ripe for takeover and here are three reasons why that may be the case.

Low Valuation

After being on the end of multiple bribery allegations in recent months, sentiment in GlaxoSmithKline has weakened severely. This has pushed shares downwards and means that GlaxoSmithKline now trades on a very low valuation.

For instance, its price to earnings (P/E) ratio is just 14.9 and its dividend yield is 5.7%. While the latter is undoubtedly impressive at first glance, the former may seem less so at a time when the FTSE 100 has a P/E ratio of just 13.4. However, when you consider that AbbVie bid for pharmaceutical peer Shire recently when it was trading on a P/E of above 20, you can see that, on a relative basis, GlaxoSmithKline seems to offer great value for money.

An Impressive Pipeline

Although sentiment in GlaxoSmithKline is weak at the moment, in the long run the success or failure of pharmaceutical stocks tends to be reliant upon their pipelines. In this respect, GlaxoSmithKline has huge potential and, moving forward, this could be a major positive for a potential buyer.

Furthermore, GlaxoSmithKline continues to increase focus on its pipeline, with the sale of consumer brands such as Ribena and Lucozade turning the business into a pure pharmaceutical play. For sector peers, this makes the company even more appealing, since the development of new, blockbuster drugs is where the potential for strong sales growth is most prevalent.

Recent Chinese Fine

Although clearly negative in the short run, GlaxoSmithKline’s recent £300 million fine for alleged bribery in China could help to encourage bids for the company. In other words, while the investigation was ongoing, a bid was less likely as there was greater uncertainty surrounding the company’s future. So, now that it has been fined, GlaxoSmithKline can, to an extent, draw a line under the Chinese bribery allegations and move ahead with developing more blockbuster drugs. This increased certainty, plus a low valuation and impressive pipeline, could mean a bid is much more likely. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »